1952 — Everest Medicines Share News
0.000.00%
Last trade - 00:00- HK$11.47bn
- HK$11.42bn
- CNY1.71bn
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Everest Medicines Says CBC Group Purchases 679,000 Shares For Hk$18.9 Million On June 8-9
Brief: Everest Medicines Enters Agreement For Exclusive LNZ100 License In Greater China
Brief: Everest Medicines Says CBC Group Buys 690,000 Co Shares For HK$20 MLN
Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion
Brief: Everest Medicines Says From 20 May To 21 May, CBC Group Buys 600,500 Shares For HK$19.2 Mln
Brief: Everest Medicines Says Aggregate Consideration Under Share Purchase Agreement Is $250 Million
Brief: Everest Medicines Says Honorary Chairman Purchases 860,000 Shares For HK$32.7 Million On March 27
Brief: Everest Medicines Posts Net Loss For Year RMB297.8 Million
Brief: Everest Medicines Says Unit To Buy Assets For Up To $50 Million
Brief: Everest Medicines Inks Agreement With Micot To Commercialize MT1013
Brief: Everest Medicines Says Chairman Purchases 30,000 Shares For HK$1.139 Million
Brief: Everest Medicines Aware That Generic Drug To Nefecon Approved By NMPA In China
Everest Medicines at 4-week high as key shareholder, executives buy shares
Brief: Everest Medicines Says Chairman, Others Purchased Shares Of Co On Dec 12